Merry Life Launches Global Phase II Trial of TML-6, The First Drug Targeted at Autolysosome pathway for Therapy of Alzheimer's Disease

Merry Life Biomedical Company, Ltd. New York Taiwan

View original content:https://www.prnewswire.co.uk/news-releases/merry-life-launches-global-phase-ii-trial-of-tml-6-the-first-drug-targeted-at-autolysosome-pathway-for-therapy-of-alzheimers-disease-302478755.html